GLP-1-based therapies
GLP-1-based therapies has been studied in 13 papers since 2025: none in people yet, 13 reviews; 12 in the past year. No study of it in people or animals has been published yet. The newest paper, Nov 5, 2026: “Obesity pharmacotherapies and cognition”.
13 papers study it13 findingsUpdated
8 new papers in 30 daysSee all 13 papers on GLP-1-based therapies
At a glance
The findings reach people, from one lab or study. 3 independent labs in 9 countries.
None of its findings points the other way.
- 3 independent labs in 9 countries
- Funders: American Diabetes Association and 5 more
What did studies of GLP-1-based therapies find?
7Studies of GLP-1-based therapies measured 7 outcomes; the most studied are body weight (3 studies), blood pressure (1) and binge-eating episodes (1).
Body weight
downin humans3
3 studies
Body weight
downin humans3
GLP-1-based therapies decrease body weight in humans (placebo-controlled trial in binge-eating disorder).
“a placebo-controlled trial found greater weight loss without a significant between-group difference in binge-eating episodes.”
Reviewplacebo-controlled trial in binge-eating disorder
GLP-1-Based Therapies in Eating Disorder Recovery
Pharmaceuticals (Basel, Switzerland)
GLP-1-based therapies decrease body weight in people with and without diabetes.
“GLP-1-based therapies are also employed for their potent weight-lowering effects in people with and without diabetes.”
Reviewin people with and without diabetes
European journal of internal medicine
GLP-1-based therapies decrease body weight in humans.
“despite their impressive weight reduction capabilities”
Review
Obesity pillars
Blood pressure
downin humans1
1 study
Blood pressure
downin humans1
GLP-1-based therapies decrease blood pressure in humans (Cardiovascular risk factors or established cardiovascular disease).
“GLP-1-based therapies are associated with modest BP reductions, but most evidence comes from trials in which BP was not the primary endpoint.”
ReviewCardiovascular risk factors or established cardiovascular disease3 to 282 weeksn = 127,101
AHA Scientific Sessions 2026 abstract
Binge-eating episodes
no changein humans1
1 study
Binge-eating episodes
no changein humans1
GLP-1-based therapies showed no clear effect on binge-eating episodes in humans (placebo-controlled trial in binge-eating disorder).
“a placebo-controlled trial found greater weight loss without a significant between-group difference in binge-eating episodes.”
Reviewplacebo-controlled trial in binge-eating disorder
GLP-1-Based Therapies in Eating Disorder Recovery
Pharmaceuticals (Basel, Switzerland)
Prandial insulin requirements
downin humans1
1 study
Prandial insulin requirements
downin humans1
GLP-1-based therapies decrease prandial insulin requirements in humans (appropriately selected patients with insulin-treated type 2 diabetes).
“the strongest direct evidence supporting reduction or withdrawal of prandial insulin in appropriately selected patients.”
Reviewappropriately selected patients with insulin-treated type 2 diabetes
Cureus
Long-term outcomes in type 2 diabetes
upin humans1
1 study
Long-term outcomes in type 2 diabetes
upin humans1
GLP-1-based therapies improve long-term outcomes in type 2 diabetes in humans (earlier use, potentially from diagnosis).
“earlier use, potentially from diagnosis, of sodium-glucose cotransporter 2 (SGLT2) inhibitors or/and glucagon-like peptide-1 (GLP-1)-based therapies to offer organ protection and improve long-term outcomes in type 2 diabetes is advocated”
Reviewearlier use, potentially from diagnosis
Diabetologia
Functional capacity
upin humans1
1 study
Functional capacity
upin humans1
GLP-1-based therapies improve functional capacity in humans (obesity-related heart failure with preserved ejection fraction).
“Existing reviews also consistently suggested improvements in functional status.”
Reviewobesity-related heart failure with preserved ejection fraction
Frontiers in cardiovascular medicine
Chronic kidney disease progression
downin humans1
1 study
Chronic kidney disease progression
downin humans1
GLP-1-based therapies decrease chronic kidney disease progression in humans (kidney-specific trials).
“kidney-specific trials show significant slowing of disease progression.”
Reviewkidney-specific trialskidney
Diabetology
What is GLP-1-based therapies linked with?
4Studies link GLP-1-based therapies with 4 measures, most often binge-eating symptoms (1 study), heart failure hospitalization (1) and cardiovascular disease (1).
Binge-eating symptoms
downin humans1
1 study
Binge-eating symptoms
downin humans1
GLP-1-based therapies are associated with binge-eating symptoms in humans.
“Some observational findings suggest reductions in binge-eating symptoms”
Review
GLP-1-Based Therapies in Eating Disorder Recovery
Pharmaceuticals (Basel, Switzerland)
Heart failure hospitalization
downin humans1HR 0.78
1 study
Heart failure hospitalization
downin humans1HR 0.78
GLP-1-based therapies are associated with heart failure hospitalization in humans (Estimate reported by the included review by Diallo et al) (HR 0.78 (95% CI 0.73–0.84)).
“For heart failure hospitalization, the review by Diallo et al. reported HR 0.78 (95% CI 0.73-0.84; n = 25,440).”
ReviewEstimate reported by the included review by Diallo et aln = 25,440
Frontiers in cardiovascular medicine
Cardiovascular disease
downin humans1
1 study
Cardiovascular disease
downin humans1
GLP-1-based therapies lower the risk of cardiovascular disease in humans (patients with type 2 diabetes).
“clear evidence that they reduce risks of cardiovascular disease and kidney outcomes in patients with type 2 diabetes”
Reviewpatients with type 2 diabetes
European journal of internal medicine
Major adverse cardiovascular events
downin humans1
1 study
Major adverse cardiovascular events
downin humans1
GLP-1-based therapies lower the risk of major adverse cardiovascular events in humans (populations with and without type 2 diabetes mellitus).
“Trials consistently demonstrate reductions in major adverse cardiovascular events across populations with and without T2DM”
Reviewpopulations with and without type 2 diabetes mellitus
Diabetology